Roxadustat vs Vadadustat
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: HIF prolyl hydroxylase (HIF-PH1/2/3) · full Chronic Kidney Disease pipeline
Roxadustat · Evrenzo
Marketed by Kyntra Bio and partners
NCT01750190 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled Phase 3 trial in 922 non-dialysis CKD patients with anemia. The two primary efficacy endpoints—mean change in hemoglobin over weeks 28-52 and hemoglobin response during the first 24 weeks—were both statistically significant and strongly favored roxadustat over placebo (p<0.0001 for both). The study was adequately powered and used a hard hemoglobin-based clinical endpoint, supporting a strong design and result.
Next expected readout: October 2027 · NCT05970172 (registry estimate)
Reported efficacy
United States (US FDA) Submission: Mean Change From Baseline in Hb (g/dL) Over Weeks 28 to 52 Regardless of Rescue Therapy (Baseline (Day 1, Week 0), Weeks 28 to 52); Ex-US Submission: Number (%) of Participants Who Achieved a Hb Response During the First 24-Weeks of Treatment Censoring for Rescue Therapy (Baseline up to Week 24): Mean hemoglobin change over Weeks 28-52: 2.00 g/dL roxadustat vs 0.16 g/dL placebo; least-squares mean difference 1.85 g/dL (95% CI 1.735-1.967; p<0.0001). Hemoglobin response during the first 24 weeks: 523/608 roxadustat vs 20/305 placebo; odds ratio 77.56 (95% CI 44.73-134.48; p<0.0001). (met)
Result source: NCT01750190
Vadadustat · Vafseo
Marketed by Akebia Therapeutics and partners
NCT02648347 · Phase 3 · completed
Participants were randomized to vadadustat or active treatment with darbepoetin alfa, but the trial was open-label; 879 received vadadustat and 872 received darbepoetin alfa. The hemoglobin primary endpoint met the prespecified non-inferiority criterion, while the primary cardiovascular safety comparison did not, making the findings mixed rather than clearly positive.
Next expected readout: April 2027 · NCT07565701 (registry estimate)
Reported efficacy
Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) (Baseline; Weeks 24 to 36); Median Time to First Major Adverse Cardiovascular Event (MACE) (Up to Week 208): Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) (Baseline; Weeks 24 to 36): Vadadustat 0.41 Grams per deciliter (g/dL) (Standard Error 0.036) vs Darbepoetin Alfa 0.42 Grams per deciliter (g/dL) (Standard Error 0.037) (mixed)
Result source: NCT02680574
Results for Chronic Kidney Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Roxadustat | Vadadustat |
|---|---|---|
| Kidney composite outcome | —Trial running · NCT05970172 | —Not posted · NCT02892149 |
| UACR, % change | —Trial running · NCT05970172 | —Not posted · NCT02892149 |
| eGFR slope | -2.6 vs -3.2+0.6 vs placeboNCT01887600 | —Not posted · NCT02892149 |
| Haemoglobin, change | 2 vs 0.2+1.8 vs placeboNCT01750190169 other results
| 1.4 vs 1.4vs Darbepoetin AlfaNCT0264834734 other results
|
Kidney composite outcome
- Roxadustat
- —Trial running · NCT05970172
- Vadadustat
- —Not posted · NCT02892149
UACR, % change
- Roxadustat
- —Trial running · NCT05970172
- Vadadustat
- —Not posted · NCT02892149
eGFR slope
- Roxadustat
- -2.6 vs -3.2+0.6 vs placeboNCT01887600
- Vadadustat
- —Not posted · NCT02892149
Haemoglobin, change
- Roxadustat
- 2 vs 0.2+1.8 vs placeboNCT01750190
169 other results
- 1.8 vs 0.4 NCT02174627
- 2.0 vs 0.3 NCT01887600
- 2.6 vs 2.4 NCT02052310
- 0.4 vs -0.1 NCT02273726
- 0.4 vs 0.2 NCT02278341
- 0.4 vs 0.2 NCT02278341
- 0.8 vs 0.7 NCT02174731
- 0.5 vs -0.0 NCT02273726
- 1.9 vs 0.3 NCT01887600
- 1.8 vs 0.6 NCT02174627
- 2.0 vs 0.3 NCT01887600
- 1.9 vs 0.2 NCT01887600
- 2.0 vs 0.2 NCT01750190
- 2.0 vs 0.2 NCT01750190
- 1.7 vs 0.2 NCT01887600
- 1.7 vs 0.1 NCT01887600
- 2.0 vs 0.4 NCT01887600
- 1.6 vs 0.2 NCT01887600
- 2.1 vs 0.4 NCT01887600
- 1.9 vs 0.4 NCT01887600
- 1.9 vs 0.3 NCT01887600
- 1.8 vs 0.3 NCT01887600
- 2.0 vs 0.4 NCT01887600
- 1.9 vs 0.7 NCT01887600
- 1.8 vs 0.4 NCT01887600
- 1.8 vs 0.3 NCT01887600
- 1.9 vs 0.2 NCT01887600
- 2.2 vs 0.4 NCT01887600
- 1.9 vs 0.5 NCT01887600
- 2.1 vs 0.2 NCT01887600
- 2.4 vs 0.4 NCT01887600
- 1.6 vs 0.4 NCT01887600
- 2.2 vs 0.2 NCT01887600
- 2.4 vs 0.3 NCT01887600
- 1.8 vs 0.4 NCT01887600
- 2.1 vs 0.2 NCT01887600
- 2.2 vs 0.2 NCT01887600
- 1.7 vs 0.1 NCT01887600
- 1.9 vs 0.1 NCT01887600
- 1.6 vs 0.1 NCT01887600
- 1.8 vs 0.3 NCT01887600
- 1.0 vs 0.0 NCT01887600
- 0.4 vs -0.0 NCT01887600
- 1.9 vs 0.5 NCT01887600
- 2.1 vs 0.5 NCT01887600
- 2.0 vs 0.4 NCT01887600
- 1.9 vs 0.3 NCT01887600
- 1.8 vs 0.3 NCT01887600
- 2.6 vs 2.4 NCT02052310
- 0.4 vs 0.2 NCT02278341
- 0.2 vs 0.1 NCT02278341
- 0.2 vs 0.1 NCT02278341
- 0.3 vs 0.3 NCT02278341
- 0.4 vs 0.2 NCT02278341
- 0.2 vs 0.1 NCT02278341
- 0.2 vs -0.1 NCT02278341
- 0.5 vs 0.2 NCT02278341
- 0.3 vs 0.1 NCT02278341
- 0.4 vs 0.1 NCT02278341
- 0.3 vs 0.1 NCT02278341
- 0.1 vs -0.0 NCT02278341
- 0.3 vs 0.1 NCT02278341
- 0.5 vs 0.3 NCT02278341
- 0.4 vs 0.2 NCT02278341
- 0.3 vs 0.1 NCT02278341
- 0.3 vs 0.1 NCT02278341
- 0.3 vs 0.1 NCT02278341
- 0.5 vs 0.2 NCT02278341
- 0.4 vs 0.0 NCT02278341
- 0.6 vs 0.2 NCT02278341
- 0.5 vs 0.0 NCT02278341
- 0.7 vs 0.1 NCT02278341
- 0.6 vs -0.0 NCT02278341
- 0.8 vs 0.1 NCT02278341
- 0.7 vs -0.0 NCT02278341
- 0.9 vs 0.1 NCT02278341
- 0.7 vs -0.0 NCT02278341
- 0.8 vs 0.1 NCT02278341
- 0.6 vs 0.1 NCT02278341
- 0.9 vs 0.7 NCT02174731
- 2.3 vs 2.5 NCT02052310
- 0.6 vs -0.0 NCT02273726
- 0.1 vs -0.0 NCT02278341
- 0.3 vs 0.1 NCT02278341
- 0.0 vs -0.0 NCT02278341
- 0.4 vs 0.2 NCT02278341
- 0.1 vs -0.1 NCT02278341
- 0.3 vs 0.1 NCT02278341
- 0.5 vs 0.1 NCT02278341
- 0.2 vs 0.1 NCT02278341
- 0.2 vs 0.1 NCT02278341
- 0.8 vs 0.6 NCT02174731
- 2.7 vs 2.5 NCT02052310
- 1.2 vs 0.0 NCT00761657
- 1.5 vs 0.0 NCT00761657
- 0.8 vs 0.0 NCT00761657
- 1.3 vs 0.0 NCT00761657
- 0.5 vs 0.0 NCT00761657
- 0.1 vs 0.0 NCT00761657
- 0.6 vs 0.0 NCT00761657
- 0.2 vs 0.0 NCT00761657
- 0.7 vs -2.5 NCT01147666
- -2.0 vs -2.4 NCT01147666
- -0.4 vs -2.5 NCT01147666
- -0.6 vs -2.5 NCT01147666
- -0.1 vs -2.4 NCT01147666
- -0.3 vs -2.4 NCT01147666
- -0.1 vs -2.4 NCT01147666
- -0.1 vs -2.4 NCT01147666
- 0.5 vs -2.4 NCT01147666
- -0.0 vs -2.4 NCT01147666
- 0.3 vs -2.4 NCT01147666
- 0.0 vs -2.4 NCT01147666
- 0.6 vs -2.4 NCT01147666
- 0.2 vs -2.4 NCT01147666
- 0.5 vs -2.4 NCT01147666
- 0.1 vs -2.4 NCT01147666
- 0.3 vs -2.5 NCT01147666
- -0.1 vs -2.5 NCT01147666
- 0.9 vs -2.5 NCT01147666
- -0.6 vs -2.5 NCT01147666
- -0.3 vs -2.4 NCT01147666
- -0.3 vs -2.4 NCT01147666
- -0.3 vs -2.4 NCT01147666
- -0.1 vs -2.4 NCT01147666
- -0.2 vs -2.4 NCT01147666
- 0.0 vs -2.4 NCT01147666
- -0.2 vs -2.5 NCT01147666
- -0.4 vs -2.5 NCT01147666
- -0.8 vs -2.5 NCT01147666
- -0.3 vs -2.5 NCT01147666
- -0.6 vs -2.5 NCT01147666
- -0.8 vs -2.4 NCT01147666
- -0.3 vs -2.4 NCT01147666
- -0.1 vs -2.4 NCT01147666
- -0.5 vs -2.4 NCT01147666
- -0.3 vs -2.4 NCT01147666
- 0.0 vs -2.4 NCT01147666
- -0.4 vs -2.4 NCT01147666
- -0.2 vs -2.4 NCT01147666
- 0.3 vs -2.4 NCT01147666
- -0.6 vs -2.4 NCT01147666
- -0.3 vs -2.4 NCT01147666
- 0.4 vs -2.4 NCT01147666
- -0.6 vs -2.4 NCT01147666
- -0.3 vs -2.4 NCT01147666
- 0.3 vs -2.4 NCT01147666
- -0.5 vs -2.4 NCT01147666
- -0.3 vs -2.4 NCT01147666
- 0.2 vs -2.4 NCT01147666
- -0.3 vs -2.5 NCT01147666
- -0.5 vs -2.5 NCT01147666
- 0.2 vs -2.5 NCT01147666
- 0.1 vs -2.5 NCT01147666
- -2.8 vs -2.5 NCT01147666
- 0.1 vs -2.4 NCT01147666
- -3.0 vs -2.4 NCT01147666
- -0.3 vs -2.4 NCT01147666
- -2.7 vs -2.4 NCT01147666
- -0.1 vs -2.4 NCT01147666
- -2.3 vs -2.4 NCT01147666
- -0.1 vs -2.4 NCT01147666
- -0.1 vs -2.4 NCT01147666
- -1.5 vs -2.4 NCT01147666
- 0.1 vs -2.4 NCT01147666
- -0.9 vs -2.4 NCT01147666
- 0 vs -2.5 NCT01147666
- -0.9 vs -2.5 NCT01147666
- -2.6 vs -2.5 NCT01147666
- Vadadustat
- 1.4 vs 1.4vs Darbepoetin AlfaNCT02648347
34 other results
- 0.4 vs 0.4 NCT02680574
- 1.5 vs 1.5 NCT02648347
- 0.2 vs 0.4 NCT02892149
- 1.4 vs 1.5 NCT02865850
- 0.9 vs -0.1 NCT01906489
- 0.7 vs -0.2 NCT01906489
- 0.8 vs -0.2 NCT01906489
- 0.9 vs -0.2 NCT01906489
- 0.7 vs -0.4 NCT01906489
- 0.6 vs -0.4 NCT01906489
- 0.4 vs -0.3 NCT01906489
- 0.1 vs -0.2 NCT01906489
- 1.4 vs -0.0 NCT01381094
- 1.1 vs 0.1 NCT01381094
- 0.5 vs 0.1 NCT01381094
- 0.3 vs 0.0 NCT01381094
- 1.3 vs -0.0 NCT01381094
- 0.8 vs 0.1 NCT01381094
- 0.5 vs 0.1 NCT01381094
- 0.3 vs 0.0 NCT01381094
- 0.7 vs -0.0 NCT01381094
- 0.4 vs 0.1 NCT01381094
- 0 vs 0.1 NCT01381094
- -0.1 vs 0.0 NCT01381094
- 0.8 vs -0.0 NCT01381094
- 0.5 vs 0.1 NCT01381094
- 0.2 vs 0.1 NCT01381094
- 0.1 vs 0.0 NCT01381094
- -0.2 vs 0.1 NCT03799627
- -0.2 vs 0.1 NCT03799627
- 0.1 vs 0.1 NCT03799627
- -0.5 vs 0.1 NCT03799627
- -0.4 vs 0.1 NCT03799627
- -0.3 vs 0.1 NCT03799627
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety
Coverage. Roxadustat: 8 of 8 rows · Vadadustat: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Roxadustat Rows use multiple source trials | Vadadustat Rows use multiple source trials |
|---|---|---|
| Hemoglobin responder rate · % of participants | 84.2% (n=386) vs 82.4% (n=397) ESA @ 36wka,b,c,d,e NCT02278341 · Phase 3 · registry result, not featured evidence show 1 more dose83.1% (n=413) vs 82.1% (n=420) ESA @ 36wk NCT02278341 · Phase 3 · registry result, not featured evidence | 42.9% (n=7) vs 60.9% (n=23) Epoetin Alfa @ 20wk*300 mga,b,c,d,e NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted show 5 more doses38.5% (n=26) vs 60.9% (n=23) Epoetin Alfa @ 20wk*300 mg NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 10 Participants as posted 33.3% (n=3) vs 60.9% (n=23) Epoetin Alfa @ 20wk*600 mg NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted 20% (n=10) vs 60.9% (n=23) Epoetin Alfa @ 20wk*600 mg NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 2 Participants as posted 35.7% (n=14) vs 60.9% (n=23) Epoetin Alfa @ 20wk*450 mg NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 5 Participants as posted 45.8% (n=24) vs 60.9% (n=23) Epoetin Alfa @ 20wk*450 mg NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 11 Participants as posted |
| Hemoglobin Change g/dL absolute change · g/dL No placebo or comparator arm | 0.46 g/dLb,c,d,f NCT04410198 · Phase 3 · registry result, not featured evidence 6 other source trials2.42 g/dL @ 16wkTiered, Weight Based Dosing TIW NCT01244763 · Phase 2 · registry result, not featured evidence 2.32 g/dL @ 16wkTiered, Weight Based Dosing TIW Then BIW NCT01244763 · Phase 2 · registry result, not featured evidence 1.85 g/dL @ 16wk50 mg TIW NCT01244763 · Phase 2 · registry result, not featured evidence 2.21 g/dL @ 16wk100 mg TIW NCT01244763 · Phase 2 · registry result, not featured evidence 1.37 g/dL @ 16wkTiered, Weight Based Dosing BIW Then QW NCT01244763 · Phase 2 · registry result, not featured evidence 1.42 g/dL @ 16wk70 mg BIW Then QW NCT01244763 · Phase 2 · registry result, not featured evidence | -0.03 g/dL @ 16wk300 mg Once Daily (QD)a,b,c,d,f NCT02260193 · Phase 2 · registry result, not featured evidence show 2 more doses-0.06 g/dL @ 16wk450 mg 3 Times Per Week (TIW) NCT02260193 · Phase 2 · registry result, not featured evidence -0.13 g/dL @ 16wk450 mg QD NCT02260193 · Phase 2 · registry result, not featured evidence |
| Hemoglobin Level g/dL absolute value · g/dL | 11.106 vs 9.468 placebo g/dLa,b,c,d,f NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 show 2 more doses10.984 vs 9.381 placebo g/dL NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 10.816 vs 9.324 placebo g/dL NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 | 10.88 vs 9.93 placebo g/dL @ 20wkb,c,d,f NCT01906489 · Phase 2 · registry result, not featured evidence |
| Time to Hgb Target time to event · months No placebo or comparator arm | 2.21 months*b,c,d,f NCT03461146 · Phase 3 · registry result, not featured evidence · converted to months from 67.2 days as posted 6 other source trials0.92 months*Tiered, Weight Based Dosing TIW NCT01244763 · Phase 2 · registry result, not featured evidence · converted to months from 28 days as posted 0.92 months*Tiered, Weight Based Dosing TIW Then BIW NCT01244763 · Phase 2 · registry result, not featured evidence · converted to months from 28 days as posted 1.61 months*50 mg TIW NCT01244763 · Phase 2 · registry result, not featured evidence · converted to months from 48.9 days as posted 0.92 months*100 mg TIW NCT01244763 · Phase 2 · registry result, not featured evidence · converted to months from 28 days as posted 1.15 months*Tiered, Weight Based Dosing BIW Then QW NCT01244763 · Phase 2 · registry result, not featured evidence · converted to months from 35 days as posted 1.84 months*70 mg BIW Then QW NCT01244763 · Phase 2 · registry result, not featured evidence · converted to months from 56 days as posted | 1.87 months @ 16wk*300 mga,b,c,d,f NCT03054350 · Phase 2 · registry result, not featured evidence · converted to months from 57 days as posted show 4 more doses2.6 months @ 16wk*300 mg NCT03054350 · Phase 2 · registry result, not featured evidence · converted to months from 79.2 days as posted 2.79 months @ 16wk*600 mg NCT03054350 · Phase 2 · registry result, not featured evidence · converted to months from 85 days as posted 1.79 months @ 16wk*600 mg NCT03054350 · Phase 2 · registry result, not featured evidence · converted to months from 54.6 days as posted 2.28 months @ 16wk*150 mg NCT03054350 · Phase 2 · registry result, not featured evidence · converted to months from 69.3 days as posted |
| Dropout rate | 43.3%g NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 show 40 more results22.6% NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 37.3% NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 7.7% NCT04655027 · Phase 4 · registry result, not featured evidence 18.2% NCT04410198 · Phase 3 · registry result, not featured evidence 26.5% NCT03329196 · Phase 3 · registry result, not featured evidence 25.9% NCT03439137 · Phase 3 · registry result, not featured evidence 14.3% NCT03402386 · Phase 3 · registry result, not featured evidence 12.5% NCT03461146 · Phase 3 · registry result, not featured evidence 6.1% NCT02174627 · Phase 3 · registry result, not featured evidence 6.6% NCT02174731 · Phase 3 · registry result, not featured evidence 41.2% NCT02052310 · Phase 3 · registry result, not featured evidence 65.7% NCT02273726 · Phase 3 · registry result, not featured evidence 28.4% NCT02278341 · Phase 3 · registry result, not featured evidence 66.7% NCT01630889 · Phase 2 · registry result, not featured evidence 8.3%2.0 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 0%2.0 mg/kg NCT01147666 · Phase 2 · registry result, not featured evidence 80%2.0 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 16.7%1.8 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 41.7%1.8 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 16.7%1.5 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 50%1.5 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 25%1.3 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 16.7%1.0 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 20%Weight Tiered 70-120-200 mg NCT01147666 · Phase 2 · registry result, not featured evidence 25%Weight Tiered 70-100-150 mg NCT01147666 · Phase 2 · registry result, not featured evidence 25%Weight Tiered 70-120-200 mg NCT01147666 · Phase 2 · registry result, not featured evidence 4.2%100 mg TIW NCT01244763 · Phase 2 · registry result, not featured evidence 16%70 mg BIW Then QW NCT01244763 · Phase 2 · registry result, not featured evidence 8.3%50 mg TIW NCT01244763 · Phase 2 · registry result, not featured evidence 12.5%Tiered, Weight Based Dosing TIW NCT01244763 · Phase 2 · registry result, not featured evidence 12.5%Tiered, Weight Based Dosing TIW Then BIW NCT01244763 · Phase 2 · registry result, not featured evidence 12.5%Tiered, Weight Based Dosing BIW Then QW NCT01244763 · Phase 2 · registry result, not featured evidence 100%2.0 mg/kg BIW NCT00761657 · Phase 2 · registry result, not featured evidence 50%2.0 mg/kg TIW NCT00761657 · Phase 2 · registry result, not featured evidence —1.5 mg/kg BIW NCT00761657 · Phase 2 · registry result, not featured evidence —1.5 mg/kg TIW NCT00761657 · Phase 2 · registry result, not featured evidence 33.3%1.0 mg/kg BIW NCT00761657 · Phase 2 · registry result, not featured evidence 60%1.0 mg/kg TIW NCT00761657 · Phase 2 · registry result, not featured evidence —0.7 mg/kg BIW NCT00761657 · Phase 2 · registry result, not featured evidence —0.7 mg/kg TIW NCT00761657 · Phase 2 · registry result, not featured evidence | 23.8%h NCT02648347 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 show 46 more results18.3% NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 11.6% NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 19.8% NCT02892149 · Phase 3 35.5%900 mg TIW NCT04707768 · Phase 3 · registry result, not featured evidence 34.9%600 mg TIW NCT04707768 · Phase 3 · registry result, not featured evidence 55.6%300 mg NCT03799627 · Phase 2 · registry result, not featured evidence 22.9%300 mg NCT03799627 · Phase 2 · registry result, not featured evidence 40%600 mg NCT03799627 · Phase 2 · registry result, not featured evidence 61.9%600 mg NCT03799627 · Phase 2 · registry result, not featured evidence 42.9%450 mg NCT03799627 · Phase 2 · registry result, not featured evidence 32.4%450 mg NCT03799627 · Phase 2 · registry result, not featured evidence —300 mg NCT03054350 · Phase 2 · registry result, not featured evidence —300 mg NCT03054350 · Phase 2 · registry result, not featured evidence 80%300 mg NCT03054350 · Phase 2 · registry result, not featured evidence —300 mg NCT03054350 · Phase 2 · registry result, not featured evidence 13.3%300 mg NCT03054350 · Phase 2 · registry result, not featured evidence —600 mg NCT03054350 · Phase 2 · registry result, not featured evidence —600 mg NCT03054350 · Phase 2 · registry result, not featured evidence 60%600 mg NCT03054350 · Phase 2 · registry result, not featured evidence —600 mg NCT03054350 · Phase 2 · registry result, not featured evidence 13.3%600 mg NCT03054350 · Phase 2 · registry result, not featured evidence —150 mg NCT03054350 · Phase 2 · registry result, not featured evidence —150 mg NCT03054350 · Phase 2 · registry result, not featured evidence 40%150 mg NCT03054350 · Phase 2 · registry result, not featured evidence —150 mg NCT03054350 · Phase 2 · registry result, not featured evidence 26.7%150 mg NCT03054350 · Phase 2 · registry result, not featured evidence —300 mg NCT03054337 · Phase 2 · registry result, not featured evidence —300 mg NCT03054337 · Phase 2 · registry result, not featured evidence 0%300 mg NCT03054337 · Phase 2 · registry result, not featured evidence —600 mg NCT03054337 · Phase 2 · registry result, not featured evidence —600 mg NCT03054337 · Phase 2 · registry result, not featured evidence 0%600 mg NCT03054337 · Phase 2 · registry result, not featured evidence —150 mg NCT03054337 · Phase 2 · registry result, not featured evidence —150 mg NCT03054337 · Phase 2 · registry result, not featured evidence 0%150 mg NCT03054337 · Phase 2 · registry result, not featured evidence 20%300 mg Once Daily (QD) NCT02260193 · Phase 2 · registry result, not featured evidence 32.3%450 mg 3 Times Per Week (TIW) NCT02260193 · Phase 2 · registry result, not featured evidence 27.3%450 mg QD NCT02260193 · Phase 2 · registry result, not featured evidence 18.8% NCT01906489 · Phase 2 · registry result, not featured evidence 5.3%630 mg NCT01381094 · Phase 2 · registry result, not featured evidence 0%500 mg NCT01381094 · Phase 2 · registry result, not featured evidence 16.7%370 mg NCT01381094 · Phase 2 · registry result, not featured evidence 11.1%240 mg NCT01381094 · Phase 2 · registry result, not featured evidence 0% NCT01235936 · Phase 2 · registry result, not featured evidence 0%Cohort 1: CKD Stage 3 Vadadustat NCT04707573 · Phase 2 · registry result, not featured evidence 0%Cohort 2: CKD Stage 4 Vadadustat NCT04707573 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 7.6%g NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 show 40 more results0.6% NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 5.4% NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 — NCT04655027 · Phase 4 · registry result, not featured evidence 2% NCT04410198 · Phase 3 · registry result, not featured evidence 6.6% NCT03329196 · Phase 3 · registry result, not featured evidence 9.9% NCT03439137 · Phase 3 · registry result, not featured evidence 7.1% NCT03402386 · Phase 3 · registry result, not featured evidence 8.3% NCT03461146 · Phase 3 · registry result, not featured evidence — NCT02174627 · Phase 3 · registry result, not featured evidence — NCT02174731 · Phase 3 · registry result, not featured evidence 5.6% NCT02052310 · Phase 3 · registry result, not featured evidence 7.3% NCT02273726 · Phase 3 · registry result, not featured evidence 0.7% NCT02278341 · Phase 3 · registry result, not featured evidence — NCT01630889 · Phase 2 · registry result, not featured evidence 8.3%2.0 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 0%2.0 mg/kg NCT01147666 · Phase 2 · registry result, not featured evidence 20%2.0 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 0%1.8 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 0%1.8 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 8.3%1.5 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 0%1.5 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 0%1.3 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 8.3%1.0 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 0%Weight Tiered 70-120-200 mg NCT01147666 · Phase 2 · registry result, not featured evidence 0%Weight Tiered 70-100-150 mg NCT01147666 · Phase 2 · registry result, not featured evidence 0%Weight Tiered 70-120-200 mg NCT01147666 · Phase 2 · registry result, not featured evidence 0%100 mg TIW NCT01244763 · Phase 2 · registry result, not featured evidence 4%70 mg BIW Then QW NCT01244763 · Phase 2 · registry result, not featured evidence 0%50 mg TIW NCT01244763 · Phase 2 · registry result, not featured evidence 4.2%Tiered, Weight Based Dosing TIW NCT01244763 · Phase 2 · registry result, not featured evidence 0%Tiered, Weight Based Dosing TIW Then BIW NCT01244763 · Phase 2 · registry result, not featured evidence 0%Tiered, Weight Based Dosing BIW Then QW NCT01244763 · Phase 2 · registry result, not featured evidence 0%2.0 mg/kg BIW NCT00761657 · Phase 2 · registry result, not featured evidence 0%2.0 mg/kg TIW NCT00761657 · Phase 2 · registry result, not featured evidence —1.5 mg/kg BIW NCT00761657 · Phase 2 · registry result, not featured evidence —1.5 mg/kg TIW NCT00761657 · Phase 2 · registry result, not featured evidence 0%1.0 mg/kg BIW NCT00761657 · Phase 2 · registry result, not featured evidence 10%1.0 mg/kg TIW NCT00761657 · Phase 2 · registry result, not featured evidence —0.7 mg/kg BIW NCT00761657 · Phase 2 · registry result, not featured evidence —0.7 mg/kg TIW NCT00761657 · Phase 2 · registry result, not featured evidence | —h NCT02648347 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 show 46 more results— NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 — NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 — NCT02892149 · Phase 3 11.8%900 mg TIW NCT04707768 · Phase 3 · registry result, not featured evidence 5.9%600 mg TIW NCT04707768 · Phase 3 · registry result, not featured evidence 0%300 mg NCT03799627 · Phase 2 · registry result, not featured evidence 2.9%300 mg NCT03799627 · Phase 2 · registry result, not featured evidence 40%600 mg NCT03799627 · Phase 2 · registry result, not featured evidence 23.8%600 mg NCT03799627 · Phase 2 · registry result, not featured evidence 9.5%450 mg NCT03799627 · Phase 2 · registry result, not featured evidence 5.9%450 mg NCT03799627 · Phase 2 · registry result, not featured evidence —300 mg NCT03054350 · Phase 2 · registry result, not featured evidence —300 mg NCT03054350 · Phase 2 · registry result, not featured evidence —300 mg NCT03054350 · Phase 2 · registry result, not featured evidence —300 mg NCT03054350 · Phase 2 · registry result, not featured evidence —300 mg NCT03054350 · Phase 2 · registry result, not featured evidence —600 mg NCT03054350 · Phase 2 · registry result, not featured evidence —600 mg NCT03054350 · Phase 2 · registry result, not featured evidence —600 mg NCT03054350 · Phase 2 · registry result, not featured evidence —600 mg NCT03054350 · Phase 2 · registry result, not featured evidence —600 mg NCT03054350 · Phase 2 · registry result, not featured evidence —150 mg NCT03054350 · Phase 2 · registry result, not featured evidence —150 mg NCT03054350 · Phase 2 · registry result, not featured evidence —150 mg NCT03054350 · Phase 2 · registry result, not featured evidence —150 mg NCT03054350 · Phase 2 · registry result, not featured evidence —150 mg NCT03054350 · Phase 2 · registry result, not featured evidence —300 mg NCT03054337 · Phase 2 · registry result, not featured evidence —300 mg NCT03054337 · Phase 2 · registry result, not featured evidence —300 mg NCT03054337 · Phase 2 · registry result, not featured evidence —600 mg NCT03054337 · Phase 2 · registry result, not featured evidence —600 mg NCT03054337 · Phase 2 · registry result, not featured evidence —600 mg NCT03054337 · Phase 2 · registry result, not featured evidence —150 mg NCT03054337 · Phase 2 · registry result, not featured evidence —150 mg NCT03054337 · Phase 2 · registry result, not featured evidence —150 mg NCT03054337 · Phase 2 · registry result, not featured evidence 10%300 mg Once Daily (QD) NCT02260193 · Phase 2 · registry result, not featured evidence 3.2%450 mg 3 Times Per Week (TIW) NCT02260193 · Phase 2 · registry result, not featured evidence 12.1%450 mg QD NCT02260193 · Phase 2 · registry result, not featured evidence 7.2% NCT01906489 · Phase 2 · registry result, not featured evidence 5.3%630 mg NCT01381094 · Phase 2 · registry result, not featured evidence 0%500 mg NCT01381094 · Phase 2 · registry result, not featured evidence 11.1%370 mg NCT01381094 · Phase 2 · registry result, not featured evidence 5.6%240 mg NCT01381094 · Phase 2 · registry result, not featured evidence — NCT01235936 · Phase 2 · registry result, not featured evidence —Cohort 1: CKD Stage 3 Vadadustat NCT04707573 · Phase 2 · registry result, not featured evidence —Cohort 2: CKD Stage 4 Vadadustat NCT04707573 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 52.5%g NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 show 40 more results64.7% NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 61.6% NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 0% NCT04655027 · Phase 4 · registry result, not featured evidence 25.6% NCT04410198 · Phase 3 · registry result, not featured evidence 27.8% NCT03329196 · Phase 3 · registry result, not featured evidence 25.3% NCT03439137 · Phase 3 · registry result, not featured evidence 28.6% NCT03402386 · Phase 3 · registry result, not featured evidence 29.2% NCT03461146 · Phase 3 · registry result, not featured evidence 57.4% NCT02174627 · Phase 3 · registry result, not featured evidence 57.6% NCT02174731 · Phase 3 · registry result, not featured evidence 44.8% NCT02052310 · Phase 3 · registry result, not featured evidence 65.4% NCT02273726 · Phase 3 · registry result, not featured evidence 50.7% NCT02278341 · Phase 3 · registry result, not featured evidence 60% NCT01630889 · Phase 2 · registry result, not featured evidence 0%2.0 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 0%2.0 mg/kg NCT01147666 · Phase 2 · registry result, not featured evidence 40%2.0 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 33.3%1.8 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 41.7%1.8 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 25%1.5 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 50%1.5 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 25%1.3 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 0%1.0 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 30%Weight Tiered 70-120-200 mg NCT01147666 · Phase 2 · registry result, not featured evidence 41.7%Weight Tiered 70-100-150 mg NCT01147666 · Phase 2 · registry result, not featured evidence 25%Weight Tiered 70-120-200 mg NCT01147666 · Phase 2 · registry result, not featured evidence 16.7%100 mg TIW NCT01244763 · Phase 2 · registry result, not featured evidence 40%70 mg BIW Then QW NCT01244763 · Phase 2 · registry result, not featured evidence 16.7%50 mg TIW NCT01244763 · Phase 2 · registry result, not featured evidence 12.5%Tiered, Weight Based Dosing TIW NCT01244763 · Phase 2 · registry result, not featured evidence 16.7%Tiered, Weight Based Dosing TIW Then BIW NCT01244763 · Phase 2 · registry result, not featured evidence 41.7%Tiered, Weight Based Dosing BIW Then QW NCT01244763 · Phase 2 · registry result, not featured evidence 0%2.0 mg/kg BIW NCT00761657 · Phase 2 · registry result, not featured evidence 0%2.0 mg/kg TIW NCT00761657 · Phase 2 · registry result, not featured evidence 0%1.5 mg/kg BIW NCT00761657 · Phase 2 · registry result, not featured evidence 0%1.5 mg/kg TIW NCT00761657 · Phase 2 · registry result, not featured evidence 0%1.0 mg/kg BIW NCT00761657 · Phase 2 · registry result, not featured evidence 0%1.0 mg/kg TIW NCT00761657 · Phase 2 · registry result, not featured evidence 0%0.7 mg/kg BIW NCT00761657 · Phase 2 · registry result, not featured evidence 30.8%0.7 mg/kg TIW NCT00761657 · Phase 2 · registry result, not featured evidence | 65.3%h NCT02648347 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 show 46 more results58.5% NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 49.7% NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 55% NCT02892149 · Phase 3 44%900 mg TIW NCT04707768 · Phase 3 · registry result, not featured evidence 45%600 mg TIW NCT04707768 · Phase 3 · registry result, not featured evidence 44.4%300 mg NCT03799627 · Phase 2 · registry result, not featured evidence 26.5%300 mg NCT03799627 · Phase 2 · registry result, not featured evidence 80%600 mg NCT03799627 · Phase 2 · registry result, not featured evidence 47.6%600 mg NCT03799627 · Phase 2 · registry result, not featured evidence 28.6%450 mg NCT03799627 · Phase 2 · registry result, not featured evidence 20%450 mg NCT03799627 · Phase 2 · registry result, not featured evidence 6.7%300 mg NCT03054350 · Phase 2 · registry result, not featured evidence 0%300 mg NCT03054350 · Phase 2 · registry result, not featured evidence —300 mg NCT03054350 · Phase 2 · registry result, not featured evidence 0%300 mg NCT03054350 · Phase 2 · registry result, not featured evidence —300 mg NCT03054350 · Phase 2 · registry result, not featured evidence 6.7%600 mg NCT03054350 · Phase 2 · registry result, not featured evidence 0%600 mg NCT03054350 · Phase 2 · registry result, not featured evidence —600 mg NCT03054350 · Phase 2 · registry result, not featured evidence 20%600 mg NCT03054350 · Phase 2 · registry result, not featured evidence —600 mg NCT03054350 · Phase 2 · registry result, not featured evidence 6.7%150 mg NCT03054350 · Phase 2 · registry result, not featured evidence 0%150 mg NCT03054350 · Phase 2 · registry result, not featured evidence —150 mg NCT03054350 · Phase 2 · registry result, not featured evidence 0%150 mg NCT03054350 · Phase 2 · registry result, not featured evidence —150 mg NCT03054350 · Phase 2 · registry result, not featured evidence 41.7%300 mg NCT03054337 · Phase 2 · registry result, not featured evidence 0%300 mg NCT03054337 · Phase 2 · registry result, not featured evidence —300 mg NCT03054337 · Phase 2 · registry result, not featured evidence 15.4%600 mg NCT03054337 · Phase 2 · registry result, not featured evidence 0%600 mg NCT03054337 · Phase 2 · registry result, not featured evidence —600 mg NCT03054337 · Phase 2 · registry result, not featured evidence 0%150 mg NCT03054337 · Phase 2 · registry result, not featured evidence 0%150 mg NCT03054337 · Phase 2 · registry result, not featured evidence —150 mg NCT03054337 · Phase 2 · registry result, not featured evidence 16.7%300 mg Once Daily (QD) NCT02260193 · Phase 2 · registry result, not featured evidence 25.8%450 mg 3 Times Per Week (TIW) NCT02260193 · Phase 2 · registry result, not featured evidence 27.3%450 mg QD NCT02260193 · Phase 2 · registry result, not featured evidence 23.9% NCT01906489 · Phase 2 · registry result, not featured evidence 5.3%630 mg NCT01381094 · Phase 2 · registry result, not featured evidence 5.9%500 mg NCT01381094 · Phase 2 · registry result, not featured evidence 16.7%370 mg NCT01381094 · Phase 2 · registry result, not featured evidence 11.1%240 mg NCT01381094 · Phase 2 · registry result, not featured evidence 0% NCT01235936 · Phase 2 · registry result, not featured evidence 0%Cohort 1: CKD Stage 3 Vadadustat NCT04707573 · Phase 2 · registry result, not featured evidence 0%Cohort 2: CKD Stage 4 Vadadustat NCT04707573 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | g constipation 16.9% (placebo 11.1%) hyperkalemia 16% (placebo 12.5%) viral upper respiratory tract infection 15.9% (placebo 13.1%) NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 show 40 more resultshypertension 28.8% oedema peripheral 14.9% nausea 10.8% NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 hypertension 21.7% (placebo 13.3%) oedema peripheral 11.3% (placebo 10.3%) viral upper respiratory tract infection 9.7% (placebo 4.4%) NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 abdominal infection 7.7% back pain 7.7% hyperkalaemia 7.7% NCT04655027 · Phase 4 · registry result, not featured evidence nasopharyngitis 24.5% diarrhoea 11.9% constipation 9.3% NCT03329196 · Phase 3 · registry result, not featured evidence nasopharyngitis 45.7% diarrhoea 15.4% contusion 13% NCT03439137 · Phase 3 · registry result, not featured evidence catheter site infection 21.4% diarrhoea 19% nasopharyngitis 14.3% NCT03402386 · Phase 3 · registry result, not featured evidence nasopharyngitis 20.8% shunt stenosis 20.8% diarrhoea 16.7% NCT03461146 · Phase 3 · registry result, not featured evidence urinary tract infection 11% (placebo 6.8%) hypertension 10.7% (placebo 8.5%) oedema peripheral 10.4% (placebo 7.7%) NCT02174627 · Phase 3 · registry result, not featured evidence diarrhoea 10.9% hypertension 8.1% headache 7.5% NCT02174731 · Phase 3 · registry result, not featured evidence hypertension 18.4% diarrhea 13.8% muscle spasms 11.5% NCT02052310 · Phase 3 · registry result, not featured evidence nausea 17% vomiting 16.2% hypertension 15.9% NCT02273726 · Phase 3 · registry result, not featured evidence hypertension 15.9% headache 8.7% diarrhoea 8% NCT02278341 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 40% cough 33.3% abdominal pain 20% NCT01630889 · Phase 2 · registry result, not featured evidence 2.0 mg/kg TIW nausea 8.3% (placebo 0%) anaemia 0% (placebo 25%) arteriovenous fistula site complication 0% (placebo 0%) NCT01147666 · Phase 2 · registry result, not featured evidence 2.0 mg/kg anaemia 0% (placebo 25%) arteriovenous fistula site complication 0% (placebo 0%) catheter site pain 0% (placebo 0%) NCT01147666 · Phase 2 · registry result, not featured evidence 2.0 mg/kg TIW cough 20% (placebo 0%) fatigue 20% (placebo 0%) haemoglobin decreased 20% (placebo 0%) NCT01147666 · Phase 2 · registry result, not featured evidence 1.8 mg/kg TIW anaemia 16.7% (placebo 25%) diarrhoea 16.7% (placebo 0%) nausea 8.3% (placebo 0%) NCT01147666 · Phase 2 · registry result, not featured evidence 1.8 mg/kg TIW diarrhoea 16.7% (placebo 0%) anaemia 0% (placebo 25%) arteriovenous fistula site complication 0% (placebo 0%) NCT01147666 · Phase 2 · registry result, not featured evidence 1.5 mg/kg TIW diarrhoea 8.3% (placebo 0%) anaemia 0% (placebo 25%) arteriovenous fistula site complication 0% (placebo 0%) NCT01147666 · Phase 2 · registry result, not featured evidence 1.5 mg/kg TIW anaemia 25% (placebo 25%) arteriovenous fistula site complication 25% (placebo 0%) catheter site pain 25% (placebo 0%) NCT01147666 · Phase 2 · registry result, not featured evidence 1.3 mg/kg TIW diarrhoea 16.7% (placebo 0%) anaemia 0% (placebo 25%) arteriovenous fistula site complication 0% (placebo 0%) NCT01147666 · Phase 2 · registry result, not featured evidence 1.0 mg/kg TIW nausea 25% (placebo 0%) diarrhoea 8.3% (placebo 0%) anaemia 0% (placebo 25%) NCT01147666 · Phase 2 · registry result, not featured evidence Weight Tiered 70-120-200 mg anaemia 20% (placebo 25%) nausea 10% (placebo 0%) arteriovenous fistula site complication 0% (placebo 0%) NCT01147666 · Phase 2 · registry result, not featured evidence Weight Tiered 70-100-150 mg anaemia 8.3% (placebo 25%) arteriovenous fistula site complication 0% (placebo 0%) catheter site pain 0% (placebo 0%) NCT01147666 · Phase 2 · registry result, not featured evidence Weight Tiered 70-120-200 mg nausea 16.7% (placebo 0%) anaemia 0% (placebo 25%) arteriovenous fistula site complication 0% (placebo 0%) NCT01147666 · Phase 2 · registry result, not featured evidence 100 mg TIW nausea 12.5% diarrhoea 8.3% headache 8.3% NCT01244763 · Phase 2 · registry result, not featured evidence 70 mg BIW Then QW oedema peripheral 16% urinary tract infection 12% nasopharyngitis 8% NCT01244763 · Phase 2 · registry result, not featured evidence 50 mg TIW oedema peripheral 16.7% dizziness 12.5% diarrhoea 8.3% NCT01244763 · Phase 2 · registry result, not featured evidence Tiered, Weight Based Dosing TIW hypertension 16.7% nausea 16.7% diarrhoea 12.5% NCT01244763 · Phase 2 · registry result, not featured evidence Tiered, Weight Based Dosing TIW Then BIW oedema peripheral 20.8% diarrhoea 16.7% urinary tract infection 16.7% NCT01244763 · Phase 2 · registry result, not featured evidence Tiered, Weight Based Dosing BIW Then QW nausea 20.8% urinary tract infection 16.7% constipation 12.5% NCT01244763 · Phase 2 · registry result, not featured evidence 2.0 mg/kg BIW fatigue 18.2% (placebo 0%) back pain 9.1% (placebo 3.6%) diarrhoea 9.1% (placebo 7.1%) NCT00761657 · Phase 2 · registry result, not featured evidence 2.0 mg/kg TIW allergic sinusitis 8.3% (placebo 0%) benign breast neoplasm 8.3% (placebo 0%) cystitis 8.3% (placebo 0%) NCT00761657 · Phase 2 · registry result, not featured evidence 1.5 mg/kg BIW headache 30% (placebo 3.6%) hyperkalaemia 20% (placebo 0%) back pain 10% (placebo 3.6%) NCT00761657 · Phase 2 · registry result, not featured evidence 1.5 mg/kg TIW hyperuricaemia 18.2% (placebo 0%) renal impairment 18.2% (placebo 0%) acidosis 9.1% (placebo 0%) NCT00761657 · Phase 2 · registry result, not featured evidence 1.0 mg/kg BIW diarrhoea 16.7% (placebo 7.1%) anorexia 8.3% (placebo 0%) chills 8.3% (placebo 0%) NCT00761657 · Phase 2 · registry result, not featured evidence 1.0 mg/kg TIW back pain 22.2% (placebo 3.6%) prostatitis 16.7% (placebo 0%) breast cyst 11.1% (placebo 0%) NCT00761657 · Phase 2 · registry result, not featured evidence 0.7 mg/kg BIW anaemia 10% (placebo 0%) hyperkalaemia 10% (placebo 0%) hypernatraemia 10% (placebo 0%) NCT00761657 · Phase 2 · registry result, not featured evidence 0.7 mg/kg TIW diarrhoea 23.1% (placebo 7.1%) abdominal pain 7.7% (placebo 0%) abdominal pain upper 7.7% (placebo 0%) NCT00761657 · Phase 2 · registry result, not featured evidence | h hypertension 17.2% diarrhoea 13% oedema peripheral 12.5% NCT02648347 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 show 37 more resultshypertension 13.9% diarrhoea 13.6% urinary tract infection 10.8% NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 hypertension 15.1% diarrhoea 10.1% nausea 7.8% NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 900 mg TIW diarrhoea 14% covid 19 12% hyperkalaemia 8.7% NCT04707768 · Phase 3 · registry result, not featured evidence 600 mg TIW covid 19 12.6% diarrhoea 10.6% nausea 7.9% NCT04707768 · Phase 3 · registry result, not featured evidence 300 mg diarrhoea 22.2% fall 11.1% hyperkalaemia 11.1% NCT03799627 · Phase 2 · registry result, not featured evidence 300 mg cough 5.9% headache 5.9% influenza 5.9% NCT03799627 · Phase 2 · registry result, not featured evidence 600 mg acarodermatitis 20% anaemia 20% back pain 20% NCT03799627 · Phase 2 · registry result, not featured evidence 600 mg diarrhoea 19% headache 14.3% hypertension 14.3% NCT03799627 · Phase 2 · registry result, not featured evidence 450 mg arteriovenous fistula thrombosis 9.5% diarrhoea 9.5% fall 4.8% NCT03799627 · Phase 2 · registry result, not featured evidence 450 mg diarrhoea 8.6% hypertension 8.6% nasopharyngitis 8.6% NCT03799627 · Phase 2 · registry result, not featured evidence 300 mg nasopharyngitis 13.3% (placebo 0%) asthma 6.7% (placebo 0%) cholelithiasis 6.7% (placebo 0%) NCT03054350 · Phase 2 · registry result, not featured evidence 300 mg blood uric acid decreased 20% (placebo 0%) nasopharyngitis 20% (placebo 0%) abdominal pain 0% (placebo 0%) NCT03054350 · Phase 2 · registry result, not featured evidence 300 mg nasopharyngitis 33.3% (placebo 0%) diarrhoea 13.3% (placebo 20%) blood parathyroid hormone increased 6.7% (placebo 0%) NCT03054350 · Phase 2 · registry result, not featured evidence 600 mg anaemia macrocytic 6.7% (placebo 0%) cardiac failure chronic 6.7% (placebo 0%) dermal cyst 6.7% (placebo 0%) NCT03054350 · Phase 2 · registry result, not featured evidence 600 mg catheter site erosion 20% (placebo 0%) conjunctivitis 20% (placebo 0%) diarrhoea 20% (placebo 20%) NCT03054350 · Phase 2 · registry result, not featured evidence 600 mg diarrhoea 13.3% (placebo 20%) abdominal pain 6.7% (placebo 0%) contusion 6.7% (placebo 0%) NCT03054350 · Phase 2 · registry result, not featured evidence 150 mg nasopharyngitis 26.7% (placebo 0%) contusion 13.3% (placebo 0%) headache 13.3% (placebo 0%) NCT03054350 · Phase 2 · registry result, not featured evidence 150 mg diarrhoea 20% (placebo 20%) headache 20% (placebo 0%) pneumonia 20% (placebo 0%) NCT03054350 · Phase 2 · registry result, not featured evidence 150 mg arthralgia 6.7% (placebo 20%) constipation 6.7% (placebo 0%) cough 6.7% (placebo 0%) NCT03054350 · Phase 2 · registry result, not featured evidence 300 mg constipation 16.7% (placebo 0%) abdominal distension 8.3% (placebo 0%) abdominal pain 8.3% (placebo 0%) NCT03054337 · Phase 2 · registry result, not featured evidence 300 mg hypertension 25% (placebo 0%) nausea 16.7% (placebo 0%) angular cheilitis 8.3% (placebo 0%) NCT03054337 · Phase 2 · registry result, not featured evidence 600 mg benign prostatic hyperplasia 7.7% (placebo 0%) delirium 7.7% (placebo 0%) diarrhoea 7.7% (placebo 0%) NCT03054337 · Phase 2 · registry result, not featured evidence 600 mg hypertension 15.4% (placebo 0%) aspartate aminotransferase increased 7.7% (placebo 0%) back pain 7.7% (placebo 0%) NCT03054337 · Phase 2 · registry result, not featured evidence 150 mg contusion 16.7% (placebo 0%) abdominal distension 8.3% (placebo 0%) back pain 8.3% (placebo 0%) NCT03054337 · Phase 2 · registry result, not featured evidence 150 mg influenza 8.3% (placebo 0%) oedema due to renal disease 8.3% (placebo 0%) orthostatic hypotension 8.3% (placebo 0%) NCT03054337 · Phase 2 · registry result, not featured evidence 300 mg Once Daily (QD) diarrhoea 13.3% nausea 13.3% arteriovenous fistula site complication 10% NCT02260193 · Phase 2 · registry result, not featured evidence 450 mg 3 Times Per Week (TIW) nausea 12.9% back pain 9.7% headache 9.7% NCT02260193 · Phase 2 · registry result, not featured evidence 450 mg QD abdominal pain 12.1% diarrhoea 12.1% dizziness 9.1% NCT02260193 · Phase 2 · registry result, not featured evidence diarrhoea 10.1% (placebo 4.2%) nausea 10.1% (placebo 4.2%) fatigue 8% (placebo 6.9%) NCT01906489 · Phase 2 · registry result, not featured evidence 630 mg hypertension 10.5% (placebo 15.8%) abdominal pain 5.3% (placebo 0%) adverse drug reaction 5.3% (placebo 0%) NCT01381094 · Phase 2 · registry result, not featured evidence 500 mg hyperkalaemia 17.6% (placebo 5.3%) nausea 11.8% (placebo 10.5%) blood bicarbonate decreased 5.9% (placebo 0%) NCT01381094 · Phase 2 · registry result, not featured evidence 370 mg abdominal discomfort 5.6% (placebo 0%) abdominal pain upper 5.6% (placebo 0%) blood uric acid increased 5.6% (placebo 0%) NCT01381094 · Phase 2 · registry result, not featured evidence 240 mg headache 11.1% (placebo 0%) urinary tract infection 11.1% (placebo 0%) constipation 5.6% (placebo 0%) NCT01381094 · Phase 2 · registry result, not featured evidence diarrhoea 20% chills 10% constipation 10% NCT01235936 · Phase 2 · registry result, not featured evidence back pain 8.3% catheter site inflammation 8.3% oropharyngeal pain 8.3% NCT04707573 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 3 versus Phase 2.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- eAssessment timepoints differ: 36 weeks versus 20 weeks.
- fThe assessment timepoint is not available for both results.
- gPopulation comparability has not been reviewed for 38 of these studies.
- hPopulation comparability has not been reviewed for 44 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Roxadustat
show 2 more results
show 18 more results
show 1 more result
show 3 more results
show 3 more results
show 1 more result
show 2 more results
show 2 more results
show 3 more results
+ 57 further endpoints in the CSV export.
Vadadustat
show 2 more results
show 3 more results
show 4 more results
show 3 more results
show 3 more results
show 16 more results
show 5 more results
show 11 more results
show 3 more results
show 5 more results
show 8 more results
show 8 more results
+ 23 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Roxadustat's landscape · Vadadustat's landscape